Daratumumab

Daratumumab is a human IgG1κ monoclonal antibody targeting CD38, a glycoprotein highly expressed on multiple myeloma cells. It induces tumor cell death via multiple mechanisms including complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Mediocon Inc supplies pharmaceutical-grade Daratumumab for bulk pharma manufacturing.

Key Features

• Analgesic, antipyretic & anti-inflammatory
• USP/BP/IP compliant quality
• Widely used in cardiovascular therapy
• Suitable for tablet and effervescent formulations

Applications

• Multiple myeloma (relapsed/refractory)
• First-line multiple myeloma combination regimens
• Smoldering multiple myeloma (investigational)
• Oncology biologic formulation R&D

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings